HCC patients with a DTL overexpression phenotype may incur a greater risk of tumor advance, and in view of the diversity in infiltrating levels and status of immune cells between the groups of high- and low-DTL expression, patients with DTL overexpression may gain benefits from more precise immunotherapy strategies in the clinics. The gene discussed is DTL; the disease is hepatocellular carcinoma.